Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atrial Fibrillation or Flutter Clear all
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT02454283
View directory record Official record
Conditions
Atrial Fibrillation or Flutter
Interventions
Vanoxerine HCl, Placebo
Drug
Lead sponsor
Laguna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

NCT00259376
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 2 Interventional

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 2Phase 3 Interventional

Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

NCT00233441
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jul 22, 2026, 4:51 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Versatility of a Circular Multielectrode Catheter in the Individualized Recognition & Treatment of Atrial Fibrillation and Related Arrhythmias Using Pulsed Field Energy

NCT06056557
View directory record Official record
Conditions
Atrial Fibrillation, Paroxysmal or Persistent, Atrial Fibrillation and Flutter, Atrial Flutter Typical
Interventions
VARIPULSE™ catheter ablation
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 22, 2026, 4:51 PM EDT
Active, not recruiting Not applicable Interventional

RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.

NCT05883631
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia, Arrhythmias, Cardiac, Atrial Flutter, Atrial Fibrillation, Paroxysmal or Persistent, Atrial Arrhythmia, Atrial Tachycardia
Interventions
Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
Device
Lead sponsor
Cortex
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 22, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter

NCT06876896
View directory record Official record
Conditions
Intra-Abdominal Hypertension
Interventions
Accuryn Foley catheter device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

NCT02339493
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Computer Electronic Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

NCT00115791
View directory record Official record
Conditions
Atrial Flutter, Atrial Fibrillation
Interventions
RSD1235, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

NCT00953212
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
beta blockers, amiodarone, ascorbic acid
Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

NCT01976507
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
dabigatran etexilate mesylate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

NCT00126074
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Honolulu, Hawaii • Tullahoma, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 22, 2026, 4:51 PM EDT
Completed No phase listed Observational Results available

EnSite Precision Observational Study

NCT03260244
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
cardiac mapping and radiofrequency ablation procedure
Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

NCT00174785
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
4,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate

NCT05661942
View directory record Official record
Conditions
Atrial Fibrillation With Rapid Ventricular Response, Hypotension Drug-Induced
Interventions
Calcium pre-treatment, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 4:51 PM EDT
Recruiting No phase listed Observational

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT05724121
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death, Cardiac Arrhythmias, Hematologic Malignancies
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

NCT00126022
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tullahoma, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 22, 2026, 4:51 PM EDT
Not listed No phase listed Observational

PREdicting Atrial Fibrillation or Flutter

NCT01851902
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Not listed
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter

NCT01914926
View directory record Official record
Conditions
Heart Rate and Rhythm Disorders
Interventions
Metoprolol, Diltiazem
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

NCT00125320
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
RSD1235
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

NCT00126061
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 22, 2026, 4:51 PM EDT
Completed Not applicable Interventional Results available

Multipolar Mapping and Atrial Arrhythmias

NCT02307188
View directory record Official record
Conditions
Atrial Fibrillation or Atrial Flutter
Interventions
Constellation Full Contact Mapping Catheter
Device
Lead sponsor
Angelo Biviano
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jul 22, 2026, 4:51 PM EDT